Top Markets
Coin of the day
Edesa Biotech, Inc. Edesa Biotech, Inc.

Edesa Biotech, Inc.

EDSA
Rank in Stocks #25796
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering,... Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Share Price
$4.80
Market Cap
$46.24M
Change (1 day)
-16.52%
Change (1 year)
103.39%
Country
CA
Trade Edesa Biotech, Inc. (EDSA)

Category

Number of shares outstanding for Edesa Biotech, Inc. (EDSA)
Number of shares outstanding as of August 2026: 0
According to Edesa Biotech, Inc. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Edesa Biotech, Inc. (EDSA) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
253.90M -
US
62.19M -
NL
483.58M -
AU
- -
CH
396.00M -
US